Table 5.

Correlation of SMAD gene expression level with overall survival (OS) of gastric cancer patients under different Her2 status

SMADs	Her 2 status	Cases	HR (95% CI)	P-value
SMAD1	Negative	429	0.48 (0.34 − 0.68	1.6e−05*
	Positive	202	0.66 (0.45 − 0.97)	0.035*
SMAD2	Negative	532	0.52 (0.4 − 0.66	1.5e−07*
	Positive	344	1.16 (0.89 − 1.5)	0.27
SMAD3	Negative	532	1.57 (1.22 − 2.03)	0.00039*
	Positive	344	1.73 (1.33 − 2.25)	3.5e−05*
SMAD4	Negative	532	0.64 (0.51 − 0.8)	0.00013*
	Positive	344	0.72 (0.55 − 0.93)	0.012*
SMAD5	Negative	532	1.37 (1.09 − 1.72)	0.0061*
	Positive	344	1.32 (0.99 − 1.75)	0.057
SMAD6	Negative	532	1.47 (1.17 − 1.84)	0.00071*
	Positive	344	1.44 (1.09 − 1.9)	0.01*
SMAD7	Negative	532	1.52 (1.2 − 1.92)	0.00044*
	Positive	344	0.8 (0.62 − 1.04)	0.089
SMAD9	Negative	429	1.85 (1.39 − 2.47)	2.1e−05*
	Positive	202	1.7 (1.16 − 2.51)	0.0064*

*P < 0.05

Abbreviations: HER2, Human Epidermal Growth Factor Receptor-2; CI, confidence interval; HR, hazard ratio.